Literature DB >> 27184247

Better Overall Survival for Breast Cancer Patients by Adding Breast Ultrasound to Follow-Up Examinations for Early Detection of Locoregional Recurrence-A Survival Impact Study.

Wan-Chen Tsai1, Hung-Kuang Wei2, Chen-Fang Hung3, Christopher Kwang-Jane Lin4, Skye Hung-Chun Cheng5, Chii-Ming Chen6, Yong Alison Wang7.   

Abstract

We retrospectively reviewed patient records to evaluate the effectiveness of our 15 y of ultrasound (US) surveillance of recurrent breast disease in comparison with mammography (MM) and clinical examination. From 4796 stage 0-III breast cancer patients who had received surgical treatment, we identified locoregional recurrence (LRR) in 161 patients. The mean age of the 161 patients was 48 y (27-82 y), and the mean follow-up interval was 77.2 mo (11-167 mo). The methods of LRR detection, sites of LRR and overall survival (OS) were examined. Multivariate Cox survival analysis showed significantly better survival in groups detected by US (hazard ratio = 0.6, p = 0.042). The 10-y LRR OS by detection types for US (n = 69), clinical examination (n = 78) and MM (n = 8) were 58.5%, 33.1% and 100%, respectively (p = 0.0004). US was seen with better OS associated with the effective early detection of non-palpable LRR breast cancer, which is mostly not detectable on MM.
Copyright © 2016 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Clinical examination; Follow-up; Locoregional recurrence; Ultrasound

Mesh:

Year:  2016        PMID: 27184247     DOI: 10.1016/j.ultrasmedbio.2016.04.003

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  2 in total

1.  Breast ultrasound in breast cancer surveillance; incremental cancers found at what cost?

Authors:  Luke Bromley; Jennifer Xu; Su-Wen Loh; Grace Chew; Eddie Lau; Belinda Yeo
Journal:  Breast       Date:  2020-11-11       Impact factor: 4.380

2.  Associations of Estrogen Receptor, Progesterone Receptor, Human Epidemic Growth Factor Receptor-2 and Ki-67 with Ultrasound Signs and Prognosis of Breast Cancer Patients.

Authors:  Xingjuan Zhao; Xuan Yang; Lei Fu; Keda Yu
Journal:  Cancer Manag Res       Date:  2021-06-09       Impact factor: 3.989

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.